Ranitidine (Tablets 150mg, 300mg. Oral solution SF 75mg/5ml)
Formulary
The European Medicines Agency (EMA) Human Medicines Committee (CHMP) has recommended the suspensionof all ranitidine medicines due to the presence of low levels of the impurity N-nitrosodimethylamine (NDMA). (30 April 2020)
Can be opened and beads swallowed without crushing or can be mixed with food or drink
dfsdfsdfsdfdsdf
Omeprazole (Capsules 10mg, 20mg)
First Choice
Capsules are more cost effective than tablets
Most brands of capsules can be opened and beads swallowed without crushing or can be mixed with food or drink
Esomeprazole
Second Choice
Esomeprazole injection
Formulary
Lansoprazole dispersible
Formulary
Orodispersible tablets 15mg, 30mg Orodispersible tablets cost twice as much as capsules
For use in patients with swallowing difficulties or who are on enteral tube feeding
Omeprazole Dispersible tablets (Losec MUPS®)
Formulary
££ - Orodispersible tablets are significantly more expensive than capsules
For use in swallowing difficulties or via nasogastric tubes when beads in the capsules are too large and lansoprazole orodispersible are not acceptable (e.g. children with fine NG tubes)
Magnesium trisilicate with magnesium carbonate and sodium bicarbonate
Non Formulary
Pantoprazole
Non Formulary
Pantoprazole IV (Protium®)
Non Formulary
Pylobactell
Non Formulary
Rabeprazole (Pariet®)
Non Formulary
Ranitidine Bismuth Citrate (Pylorid®)
Non Formulary
Tripotassium Dictratobismuthate (De-Noltab®)
Non Formulary
Discontinued
Key
Restricted Drug
Unlicensed
Link to adult BNF
Link to children's BNF
Link to SPCs
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
ICB
Low carbon footprint
Medium carbon footprint
High carbon footprint
Status
Description
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist.
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.
Restricted
dfsdfsdfsdfdsdf
